Dare Bioscience vs Dianthus Therapeutics
DARE and DNTH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DARE and DNTH compare
Dianthus Therapeutics is the larger company, worth 471 times as much as Dare Bioscience ($5.0B against $10.6M).
Dianthus Therapeutics scores higher on the StockData Score (7 against 5 for Dare Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DARE | DNTH |
|---|---|---|
| Size and price | ||
| Market cap | $10.6M | $5.0B |
| Share price | $0.694 | $89.30 |
| Change, 1 year | −61.9% | 144% |
| Change, 5 years | −96.5% | −16.6% |
| Beta (5Y) | 1.40 | 1.44 |
| Employees | 24 | 92 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.8× | – |
| P/B | – | 4.0× |
| FCF yield | −111% | – |
| Profitability | ||
| Operating margin | −813% | – |
| Net margin | −804% | – |
| FCF margin | −861% | – |
| Return on equity | – | −22.6% |
| Return on invested capital | – | −22.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.99 | 30.02 (better) |
| Altman Z-score | −13.50 | 85.71 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −0.01% |
| Shareholder yield | 0.00% (better) | −0.01% |
| Ownership | ||
| Held by institutions | 8.5% | 118% |
| Held by insiders | 9.4% | 9.1% |
| Insider net buying, 12 months | – | −$63.8M |
| Short interest, % of float | 7.1% | 18.2% |
Go deeper
- DARE stock overview
- DARE income statement
- DARE valuation and score
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.